Timmers Tessa, van Berckel Bart N M, Lammertsma Adriaan A, Ossenkoppele Rik
Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Methods Mol Biol. 2018;1750:221-229. doi: 10.1007/978-1-4939-7704-8_15.
Alzheimer's disease is a neurodegenerative condition that is neuropathologically characterized by the presence of amyloid-β plaques and neurofibrillary tangles consisting of tau. Recently, several positron emission tomography (PET) tracers have been developed that yielded promising initial results. In this chapter, we discuss how tau PET can be used in the context in clinical trials. We argue that simplified reference tissue models based on dynamic data acquisition are most suitable for accurately measuring changes in tau pathology in trials tailored to reduce cerebral tau load. Therefore, we discuss the importance of tracer kinetic modeling and describe in detail how a reliable measurement of specific binding can be obtained.
阿尔茨海默病是一种神经退行性疾病，其神经病理学特征是存在由tau蛋白组成的淀粉样β斑块和神经原纤维缠结。最近，已经开发出几种正电子发射断层扫描（PET）示踪剂，它们取得了令人鼓舞的初步结果。在本章中，我们讨论了tau PET如何在临床试验中使用。我们认为，基于动态数据采集的简化参考组织模型最适合在旨在降低脑tau负荷的试验中准确测量tau病理学的变化。因此，我们讨论了示踪剂动力学建模的重要性，并详细描述了如何获得特定结合的可靠测量值。
Zotero 插件